Correlation Between Oncolytics Biotech and Helix BioPharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Oncolytics Biotech and Helix BioPharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncolytics Biotech and Helix BioPharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncolytics Biotech and Helix BioPharma Corp, you can compare the effects of market volatilities on Oncolytics Biotech and Helix BioPharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncolytics Biotech with a short position of Helix BioPharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncolytics Biotech and Helix BioPharma.

Diversification Opportunities for Oncolytics Biotech and Helix BioPharma

-0.27
  Correlation Coefficient

Very good diversification

The 3 months correlation between Oncolytics and Helix is -0.27. Overlapping area represents the amount of risk that can be diversified away by holding Oncolytics Biotech and Helix BioPharma Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Helix BioPharma Corp and Oncolytics Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncolytics Biotech are associated (or correlated) with Helix BioPharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Helix BioPharma Corp has no effect on the direction of Oncolytics Biotech i.e., Oncolytics Biotech and Helix BioPharma go up and down completely randomly.

Pair Corralation between Oncolytics Biotech and Helix BioPharma

Assuming the 90 days trading horizon Oncolytics Biotech is expected to under-perform the Helix BioPharma. But the stock apears to be less risky and, when comparing its historical volatility, Oncolytics Biotech is 1.62 times less risky than Helix BioPharma. The stock trades about -0.02 of its potential returns per unit of risk. The Helix BioPharma Corp is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  115.00  in Helix BioPharma Corp on August 25, 2024 and sell it today you would lose (38.00) from holding Helix BioPharma Corp or give up 33.04% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Oncolytics Biotech  vs.  Helix BioPharma Corp

 Performance 
       Timeline  
Oncolytics Biotech 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Oncolytics Biotech are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, Oncolytics Biotech may actually be approaching a critical reversion point that can send shares even higher in December 2024.
Helix BioPharma Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Helix BioPharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Oncolytics Biotech and Helix BioPharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Oncolytics Biotech and Helix BioPharma

The main advantage of trading using opposite Oncolytics Biotech and Helix BioPharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncolytics Biotech position performs unexpectedly, Helix BioPharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will offset losses from the drop in Helix BioPharma's long position.
The idea behind Oncolytics Biotech and Helix BioPharma Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio